- Home
- / GeneOne Life Science
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
GeneOne Life Science financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩2.3 K
2024-10-29
Market Capitalization
₩204.4 B
2024-10-29
Revenue
₩40.2 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 34.3B | 41.2B | 41.5B | 38.7B | 48.7B | 40.2B |
| Cost of goods sold | 18.0B | 19.9B | 11.0B | 23.5B | 25.8B | 42.4B |
| Gross profit | 20.2B | 24.2B | 34.1B | 21.2B | 24.5B | 2.7B |
| Gross profit margin, % | 58.8% | 58.7% | 82.2% | 54.8% | 50.4% | 6.7% |
| Operating expense total | 26.3B | 26.2B | 46.4B | 42.6B | 57.6B | 33.4B |
| Depreciation and amortization | 1.2B | 3.4B | 4.0B | 4.6B | 5.4B | 45.1B |
| EBITDA | (6.1B) | (2.0B) | (12.3B) | (21.4B) | (33.0B) | (30.7B) |
| EBITDA margin, % | -17.9% | -4.9% | -29.7% | -55.4% | -67.8% | -76.4% |
| EBIT | (7.4B) | (5.5B) | (17.2B) | (26.4B) | (38.6B) | (77.4B) |
| EBIT margin, % | -21.6% | -13.4% | -41.5% | -68.1% | -79.2% | -192.5% |
| Interest income | 334.9M | 259.4M | 561.2M | 1.5B | 6.2B | 518.7M |
| Interest expense | 1.4B | 2.0B | 628.5M | 4.5B | 7.3B | 1.2B |
| Pre tax profit | (11.7B) | (7.1B) | (18.2B) | (15.6B) | (38.1B) | (77.7B) |
| Income tax expense | 162.5M | 474.0M | 422.0M | 335.2M | 95.8M | 113.4M |
| Net Income | (11.9B) | (7.6B) | (18.6B) | (16.0B) | (38.2B) | (77.8B) |